CANADIAN NEUROLOGICAL SCIENCES FEDERATION
FÉDÉRATION DES SCIENCES NEUROLOGIQUES DU CANADA

The journal

Canadian Journal of Neurological Sciences

Volume 37 Number 4 July 2010



See Page A-2 for figure legend

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

PM 40007777 R 9824

https://doi.org/10.1017/S0317167100050654 Published online by Cambridge University Press

Beyond whole brain there's local control



Leksell Gamma Knife® Perfexion™ treats multiple brain metastases in a single session, reducing the damage to healthy tissue that may limit future treatment options, and allowing for concomitant chemotherapy for optimum primary tumor control. Find out how Elekta is creating new possibilities for the most challenging cases at elekta.com/proof.



Leksell Gamma Knife® Perfexion™



Single-session multiple mets

Human care makes the future possible

ELEKTA
NEUROSCIENCE

https://doi.org/10.1017/S0317167100050654 Published online by Cambridge University Press

CANADIAN NEUROLOGICAL SCIENCES FEDERATION
FÉDÉRATION DES SCIENCES NEUROLOGIQUES DU CANADA

The journal

Canadian Journal of Neurological Sciences

Volume 37 / Number 4 / July 2010

CANADIAN NEUROLOGICAL SCIENCES FEDERATION
FÉDÉRATION DES SCIENCES NEUROLOGIQUES DU CANADA

The journal

Canadian Journal of Neurological Sciences

Volume 37 / Number 4 / July 2010

COVER LEGEND

From the Neuroimaging Highlight article "Concurrence of High-Grade Brainstem Glioma and Multiple Sclerosis" pages 512-514
Middle cerebellar peduncle biopsy reveals hypercellularity
(A), no demyelination (C) and frequent atypical nuclei (B-F, arrows) of glial origin
(D) having increased proliferation (E) and expressing p53
(F), establishing the diagnosis of WHO grade III anaplastic astrocytoma. A,B – hematoxylin and eosin stain;
C – Luxol fast blue stain; D – glial fibrillary acidic protein immunostain;
E – Ki67 immunostain; F – immunostain for p53 expression.

https://doi.org/10.1017/S0317167100050654 Published online by Cambridge University Press

A complete financial diagnosis includes helpful advice and practical solutions.

At Scotiabank, we have experts that can help you grow your business. Our *Scotia Professional*® Plan is a customized financial package that includes everything you need to set up and run a successful practice. You'll get competitive financing rates, flexible payback plans, and a dedicated advisor – all in one convenient package to meet your day to day banking, financing, and investment needs. It makes managing your money easy, so you can focus on serving your patients and growing your practice.

Learn more at any Scotiabank branch or visit www.scotiabank.com/professional

Scotia Professional Plan

You're richer than you think.®

Scotiabank®

https://doi.org/10.1017/S0317167100050654 Published online by Cambridge University Press

CANADIAN NEUROLOGICAL SCIENCES FEDERATION
FÉDÉRATION DES SCIENCES NEUROLOGIQUES DU CANADA

The journal

Canadian Journal of Neurological Sciences

Volume 37 / Number 4 / July 2010

The official journal of: / La Revue officielle de:

The Canadian Neurological Society
La Société Canadienne de Neurologie

The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie

The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique

The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at:
Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est situe en permanence à:

7015 Macleod Trail SW, Suite 709
Calgary, Alberta, Canada T2H 2K6

The Canadian Journal of Neurological Sciences is published bi-monthly. The annual subscription rate for Individuals are: C$120 (Canada), C$140 (Foreign including USA). Subscription rates for Institutions are: C$150 (Canada), C$170 (Foreign including USA). See www.cjns.org for details. Single copies C$30 each plus postage and handling. Communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: journal@cjns.org; Web: www.cjns.org

Postage paid at Calgary, Alberta. This journal is indexed by *AbHyg, AgBio, BIOBASE, BiolAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerpMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, PN&I, ProtozoAb, PsycInfo, Reac, RefZh, RM&VM, RurDevAb, SCI, SCOPUS, Swets, TDB, TOCprem.*

Le Journal Canadien des Sciences Neurologiques est publié 6 fois par an. L'abonnement annuel est de 120 $C (non-membres au Canada); 140 $C (Etats Unis et ailleurs); l'abonnement annuel for pour les institutions est de 150 $C (non-membres au Canada); 170 $C (Etats Unis et ailleurs); Voir www.cjns.org pour détails. Copie simple: 30 $C plus affranchissement et manutention. Toutes les communications doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail journal@cjns.org; Web:www.cjns.org. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *AbHyg, AgBio, BIOBASE, BiolAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerpMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, PN&I, ProtozoAb, PsycInfo, Reac, RefZh, RM&VM, RurDevAb, SCI, SCOPUS, Swets, TDB, TOCprem.*

ISSN 0317 - 1671

https://doi.org/10.1017/S0317167100050654 Published online by Cambridge University Press

Thank you delegates for joining us at this years Congress in Quebec city!

We look forward to seeing you at our 2011 Congress in Vancouver, British Columbia!



Surrounded by water on three sides and nestled alongside the Coast Mountain Range, Vancouver is the largest city in the province of British Columbia with over half a million residents and one of the mildest climates in Canada. Home to spectacular natural scenery and a bustling metropolitan core, Vancouver was Host City to the Olympic and Paralympic Winter Games in 2010. Whether just relaxing in a park or bike riding around the seawall, there is always something to do in Vancouver.

Canadian Neurological Sciences Federation
Annual Congress July 14 - 17, 2011

CANADIAN NEUROLOGICAL SCIENCES FEDERATION
FÉDÉRATION DES SCIENCES NEUROLOGIQUES DU CANADA

https://doi.org/10.1017/S0317167100050654 Published online by Cambridge University Press

Fibromyalgia pain is real.
And so is treatment with LYRICA.

LYRICA is the first treatment indicated in Canada for the management of pain associated with fibromyalgia in adults

- LYRICA is proven to manage the pain associated with fibromyalgia[1]
- LYRICA has been demonstrated to significantly improve pain-related sleep difficulties[2]
  - LYRICA reduced overall MOS-Sleep Scale scores significantly more from baseline versus placebo

  [LYRICA 300 mg/day −19.1 (p=0.0174), LYRICA 450 mg/day −20.41 (p=0.0026), and LYRICA 600 mg/day −19.49 (p=0.0101) vs −14.29 for placebo][2]*

The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase.

There have been post-marketing reports of angioedema in patients, some without reported previous history/episodes, including life-threatening angioedema with respiratory compromise. Caution should be exercised in patients with previous history/episodes of angioedema and in patients who are taking other drugs associated with angioedema.

In clinical trials and in post-marketing experience, there have been reports of patients, with or without previous history, experiencing renal failure alone or in combination with other medications. Caution is advised when prescribing to the elderly or those with any degree of renal impairment.

The most commonly observed dose-related adverse events in LYRICA-treated patients were: dizziness (22.7-46.5%), somnolence (12.9-20.7%), weight gain (7.6-13.7%), peripheral edema (5.3-10.8%). The most commonly reported (≥5% and twice the rate of that seen in placebo) treatment-related adverse events were: dizziness (37.5%), somnolence (18.6%), weight gain (10.6%), dry mouth (7.9%), blurred vision (6.7%), and peripheral edema (6.1%). Adverse events were usually mild to moderate in intensity. Discontinuation rates due to adverse events for LYRICA and placebo, respectively, were 20% and 11%. There was a dose-dependent increase in rate of discontinuation due to adverse events.

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

Dosage reduction is required in patients with renal impairment (creatinine clearance <60 mL/min) and in some elderly patients as LYRICA is primarily eliminated by renal excretion.

See Prescribing Information for complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria.

References: 1. LYRICA Product Monograph. Pfizer Canada Inc., October 2009. **2.** Mease PJ *et al.* A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. *J Rheumatol* 2008;35:502-14.

* A multicenter, double-blind, 13-week, randomized trial. 748 patients who met the ACR criteria for fibromyalgia and who had an average mean pain score of ≥4 on an 11-point numeric rating scale (NRS) during the baseline assessment were randomized to LYRICA 300 mg/day (n=185), 450 mg/day (n=183), 600 mg/day (n=190), or placebo (n=190). Patients were allowed to take acetaminophen up to 4 g/day as needed for pain relief. The number of completers was: LYRICA 300 mg/day (n=123), 450 mg/day (n=121), 600 mg/day (n=111), or placebo (n=130). The primary endpoint was the reduction in endpoint mean pain scores (mean of the last 7 daily pain scores while on study medication). Pain-related sleep difficulties were assessed using the Medical Outcomes Study-Sleep Scale (MOS-SS), a scale that runs from 0-100. Mean baseline MOS-SS score for overall sleep problem index was 65.0.

Pfizer Working together for a healthier world™

PAAB Member R&D

PrLYRICA® PREGABALIN

See prescribing summary on page A-11, A-12

https://doi.org/10.1017/S0317167100050654 Published online by Cambridge University Press

https://doi.org/10.1017/S0317167100050654 Published online by Cambridge University Press

ADVERTORIAL

Integrating Strong HR Management Practices Into Your Professional Practice

No matter what the economic environment, finding and keeping the right staff is an important issue for professional practioners and small business owners. Whatever the size of your enterprise, developing sound human resources management practices and policies is not only good practice, it will also help you develop a reputation as "an employer of choice", a real advantage in attracting the best and the brightest.

Whether your practice is a start-up, or is well established, taking the time to think about the kind of culture you want to create, and then taking deliberate steps to create a positive working environment will pay big dividends. For example, will you prefer a top-down, management-driven approach to running the business, or will you cultivate a more open consultative approach? Will flexible hours be part of your workplace, or do your operations require a more regulated schedule? Each option has both strengths and weaknesses which you will want to assess.

Human resources management practices cover many areas, from creating detailed job descriptions, recruitment and retention strategies, workplace safety measures, to programs which ensure a culture of respect and fairness for all your staff. You'll need to consider record keeping, confidentiality, dismissal, and compliance policies, to name but a few.

Many professionals may not have the time or expertise to create documented policies and detailed employee handbooks. Your professional association may be a useful source of information, or alternately an on-line search may help you identify relevant resources.

Some key tips to building a strong foundation for an excellent work environment and workplace team include:

- Build an HR team that may include your accountant, lawyer, an HR consultant.
- Make sure your compensation package is competitive and attractive.
- Reward your employees with financial or non-financial incentives based on sales, performance, or customer feedback.
- Profit sharing plans can be a great way to reward employees and give them a stake in the longer-term success of the business.
- Make your employees ambassadors and consider finder's fees as part of your recruitment policy.
- Be flexible – with work hours, telecommuting, unpaid leaves, etc.
- Help your employees upgrade with training and staff development programs.
- Focus on creating a positive environment which gains a reputation as a great place to work.
- Have a clear vision statement that outlines what you want your business to be in the future. It will give you shape and direction for your long-term business goals.

Top performing staff can be a business' greatest asset. By implementing sound HR management practices, professionals can attract and keep a team of the best and brightest, who will become a strong foundation supporting a bright future for your enterprise.

To learn more, speak to a Scotiabank Small Business advisor today, or visit getgrowingforbusiness.com.

This advertorial is provided by Scotiabank & the Scotia Professional Plan

Scotia Professional Plan

https://doi.org/10.1017/S0317167100050654 Published online by Cambridge University Press